Navigation Links
Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
Date:7/8/2009

SAN FRANCISCO, July 8 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has received commitments from investors to purchase in a private placement securities of the Company for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer, acted as the exclusive placement agent for the transaction.

The net proceeds of the financing will be used to support the advancement of Nile's lead compound, CD-NP, through its 30-patient single-blind, placebo-controlled Phase 2 study, which is currently open to enrollment. This Phase 2 study is designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with acute heart failure and mild to moderate renal insufficiency. Additional exploratory endpoints will include assessments of CD-NP's ability to relieve symptoms of acute heart failure and its effects on biomarkers of heart failure and renal function.

"We are pleased to have the continued support of the investment community to ensure the advancement of our promising technology in the effort to develop a novel treatment for heart failure patients," said Joshua Kazam, Chief Executive Officer. "We believe these funds will provide us with sufficient capital to complete our impending Phase 2 clinical study of CD-NP and we look forward to generating meaningful clinical data."

Under the terms of a Securities Purchase Agreement, Nile will sell an aggregate of approximately 2.7 million shares of its common stock and warrants to purchase up approximately 2.7 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase one share of comm
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PARK, N.C. , Sept. 17, 2014  The ... presentation topics that will be featured at the conference, ... Conference Center on December 3 and 4, 2014. Researchers, ... are invited to hear the following: ... UC San Diego Skaggs School of Pharmacy ...
(Date:9/17/2014)... COLUMBIA, Md. (PRWEB) September 17, 2014 ... Nexera-e Comprehensive Two-Dimensional Liquid Chromatograph (2D-LC), which ... most complex sample matrices. The system provides ... of sample analytes, which is beneficial to ... food extracts, and natural products. , Comprehensive ...
(Date:9/17/2014)... San Jose, California (PRWEB) September 17, 2014 ... disintegrated by naturally occurring microorganisms such as bacteria, ... subsequently transformed into water, methane, biomass, inorganic compounds, ... With enhanced processability, expanding customer base and improved ... environmentally beneficial and economically viable alternative to conventional ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., ... eClinical Solutions, today announced three of its experts are ... for Clinical Data Management to be held September 28 ... . The Company also announced the innovative ... overall quality in clinical trials acquired earlier this year, ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... ON ALS CLINICALS AND DRUG DEVELOPMENT, ROCKVILLE, ... (Amex: CUR ) announced that Dr. Thomas ... President, Research. He will be,working with Dr. Karl ... the company,s upcoming clinical trial for ALS,(Amytrophic Lateral ...
... Symbol: MS, EDMONTON, July 30 /PRNewswire-FirstCall/ - BioMS ... of multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... "Focus on Healthcare Conference" in New York., ... WHERE: The Millennium Broadway Hotel, New York ...
... receives custom orders from leading semiconductor manufacturers, officially putting revenue ... ... Seattle, WA (PRWEB) July 30, 2008 -- Carbon Nanoprobes, Inc ... welcomes its first revenue from two major semiconductor manufacturers. Contracts ...
Cached Biology Technology:Neuralstem Fills Key Product Development Position 2BioMS Medical to present at BMO Healthcare Conference 2Startup Nanotech Firm Books First Revenue From Large Chip Makers 2Startup Nanotech Firm Books First Revenue From Large Chip Makers 3
(Date:9/17/2014)... decades of decline, grasses have returned to some once-denuded ... marsh in those places seems healthy again, but a ... the marsh coastal protection remains diminished. , ... hasn,t come back," said ecologist Mark Bertness, professor of ... in the journal Biological Conservation . "The metric ...
(Date:9/17/2014)... a new crime unit designed to fight food fraud ... horse meat being passed off as beef scientists ... adulteration. They describe their approach, which represents a vast ... Agricultural and Food Chemistry . , Hans-Ulrich Humpf and ... economic problem. But they also say that adding, for ...
(Date:9/17/2014)... bacterial infections, including MRSA and MSSA could be ... that mimic the scaly surface of shark skin, ... journal Antimicrobial Resistance and Infection Control . ... prevented the spread of human disease bacteria through ... is an arrangement of ridges formulated to resemble ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Sharks' skin has teeth in the fight against hospital superbugs 2
... Researchers at Indiana University School of Medicine are several steps closer ... cells could be used to let him or her hear the ... able to transform, in the laboratory, stem cells taken from adult ... nerve cells -- neurons -- found in the ear. The results ...
... at New York University and Rockefeller University have ... shown to have key roles in gene regulation, ... mammals. MicroRNAs are a recently discovered large class ... complementary sites in target messenger RNA to regulate ...
... to visualize more of the arteries in the lungs, ... seeing more may have little impact on the patient's ... 198 patients with suspected pulmonary embolism. About half of ... 100 patients had a single-detector CT examination. The radiology ...
Cached Biology News:Researchers Closer To Helping Hearing-Impaired Using Stem Cells 2NYU, Rockefeller researchers find complexity of regulation by microRNA genes 2Newer imaging techniques may lead to over-treatment 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Request Info...
... 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... to 1 mg/ml,(0.26 M to 2.6 mM) Sensitivity: around 0.2 ug/ml ...
See product name for description....
Biology Products: